Tekton Research Inc

1. Moderna TX, Inc. $23,188,461 15,957 payments
2. AstraZeneca Pharmaceuticals LP $9,393,380 35 payments
3. Pfizer Inc. $7,151,118 1,029 payments
4. Bavarian Nordic A/S $3,726,132 411 payments
5. Eli Lilly and Company $1,810,165 89 payments
6. GlaxoSmithKline, LLC. $1,535,719 456 payments
7. Janssen Research & Development, LLC $1,510,785 213 payments
8. Emergent BioSolutions Inc. $1,155,793 1,327 payments
9. Novavax Inc $1,052,122 204 payments
10. Seqirus USA Inc $838,036 199 payments

1. A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19 $9,243,104 16 payments
2. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $5,506,341 381 payments
3. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $4,103,525 6,120 payments
4. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $3,018,773 6,378 payments
5. ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 $2,914,635 164 payments
6. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age $2,861,558 92 payments
7. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $2,401,762 116 payments
8. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $2,182,856 235 payments
9. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $1,882,407 81 payments
10. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $1,460,617 2,417 payments

1. Other $119,763 26 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.